Flindr Therapeutics raised €20 million in a Series A funding led by V-Bio Ventures and other new investors to advance its pipeline of small molecule inhibitors for cancer treatment.
Flindr Therapeutics raised €20 million in a Series A funding led by V-Bio Ventures and other new investors to advance its pipeline of small molecule inhibitors for cancer treatment.
04/30/24, 5:49 PM
Location
ossMoney raised
€20 million
Industry
therapeutics
biotechnology
Investors
Brabantse Ontwikkelings Maatschappij (Bom), Swanbridge, Oncode Oncology Bridge Fund, Curie Capital, Flanders Future Tech Fund, Qbic Fund, Johnson & Johnson Innovation — Jjdc, Inc. (Jjdc), V Bio Ventures
Flindr Therapeutics, a precision oncology therapeutics company, has announced a €20 million Series A funding round led by V-Bio Ventures along with other new investors Johnson & Johnson Innovation — JJDC, Inc. (JJDC), QBIC Fund, Flanders Future Tech Fund, and Curie Capital, as well as existing investors Oncode Oncology Bridge Fund, Swanbridge, and Brabantse Ontwikkelings Maatschappij (BOM). The funding will be used to advance its pipeline of small molecule inhibitors for cancer treatment and progress its lead program to IND, develop an exciting second program, and broaden its pipeline using the ImmunoGram Drug Discovery Engine.
Company Info
Location
oss, north brabant, netherlands
Additional Info
Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine.